Chongqing Tianzhi Pharmaceutical

Chongqing Tianzhi Pharmaceutical is a Chinese pharmaceutical enterprise specializing in the research, development, manufacturing, and sale of chemical active pharmaceutical ingredients (APIs) and finished drug formulations. The company's therapeutic focus spans cardiovascular and cerebrovascular diseases, digestive system disorders, and anti-infectives. Its core product portfolio features established treatments such as Lansoprazole enteric-coated capsules, Telmisartan tablets, and Amlodipine Besylate tablets. Based in Chongqing, the company operates multiple GMP-certified production lines and integrates its R&D capabilities to support both domestic market penetration and the export of high-quality APIs. It has historically leveraged its listing on the National Equities Exchange and Quotations (NEEQ) to support its industrial expansion.